Inotrem
Paris
France
28 articles about Inotrem
-
Inotrem Successfully Reaches Agreement with the FDA for a Phase 3 Registration Trial for Nangibotide in Septic Shock
1/8/2024
Inotrem announced the outcome of its regulatory interactions with the US Food and Drug Administration to finalize the design of a single Phase 3 registration trial for nangibotide in septic shock.
-
Inotrem Receives Milestone Funding From the Crohn’s & Colitis Foundation IBD Ventures Program to Advance Its Inflammatory Bowel Disease Pipeline
11/6/2023
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced it received the second milestone-based funding from the American Crohn’s & Colitis Foundation’s IBD Ventures program.
-
Inotrem Announces Publication of Two Key Articles on Nangibotide Phase II Programs in Peer-reviewed Medical Journals
6/1/2023
Inotrem announced the publication of the results of two phase 2 clinical studies in the The Lancet Respiratory Medicine and in eClinicalMedicine.
-
Inotrem Receives Funding From the Crohn’s & Colitis Foundation to Help Develop New Therapeutic Approaches in Inflammatory Bowel Disease (IBD)
1/9/2023
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under a program to accelerate research and development that aim to improve the quality of life for patients with IBD.
-
Inotrem Announces That Its ESSENTIAL Phase II Study for the Treatment of Critically ill COVID-19 Patients Meets Its Primary and Key Secondary Endpoints
10/25/2022
Inotrem announced at the European Society of Intensive Care Medicine’s Annual Congress, held in Paris, positive results for ESSENTIAL, its Phase II clinical trial in COVID-19 patients hospitalized in critical care units and experiencing acute respiratory distress.
-
Inotrem Announces Positive Outcome of its Phase II ASTONISH Trial in Septic Shock Patients Demonstrating Efficacy of Nangibotide
10/13/2022
Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, disclosed for the first time at the International Sepsis Forum held in Barcelona the results for its Phase IIb ASTONISH clinical trial in septic shock patients.
-
Inotrem and the Crohn’s & Colitis Foundation Sign a R&D Collaboration Agreement to Support the Development of a New Therapeutic Approach in Inflammatory Bowel Disease (IBD)
4/14/2022
Inotrem announced a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD.
-
Inotrem appoints Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program Targeting Chronic Inflammatory Diseases
11/9/2021
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies targeting the TREM-1 pathway, announced the appointment of Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program.
-
Inotrem Receives Approval to Expand Nangibotide Clinical Trial in Critically Ill COVID-19 Patients and Receives Additional Public Funding of €45 Million
7/12/2021
Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in COVID-19 patients from both the French and Belgian competent authorities.
-
Inotrem Adds a New Strategic Asset to Its Immunotherapy Anti-TREM-1 Drug Pipeline
6/23/2021
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced that it has filed a patent to protect a new therapeutic modality against TREM-1, a monoclonal antibody.
-
Inotrem Announces Positive Outcome of Interim Futility Analysis for Its Phase IIB ASTONISH Trial in Septic Shock Patients to Demonstrate Nangibotide Efficacy
6/10/2021
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced that the ASTONISH Independent Data Monitoring Committee completed the planned safety and efficacy assessment for futility of the company’s ongoing Phase IIB ASTONISH trial in septic shock patients.
-
Inotrem Bolsters Leadership Team With the Appointment of Sven Zimmermann as New CEO
3/24/2021
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced the appointment of Sven Zimmermann as Chief Executive Officer, effective April 19th, 2021.
-
Inotrem’s COVID-19 Phase IIa Clinical Trial Declared “National Priority Research” by the French Government’s Clinical Trial Council
12/24/2020
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company’s lead product, for the treatment of severe forms of COVID-19 has been declared “National Priority Research” by the French government steering committee for therapeutic clinical trials and other research (CAPNET). In the context of a substant
-
Inotrem Receives Clearance From French, Belgian And US Authorities to Launch a Phase II Clinical Trial Aimed at Assessing Nangibotide in Mechanically Ventilated Patients With COVID-19
7/23/2020
Inotrem S.A. announced that it has obtained authorization to launch its phase IIa clinical trial in COVID-19 patients in France, Belgium and the USA.
-
IONTAS Announces a New Collaboration to Identify Novel Immunotherapy Targets
5/7/2020
IONTAS Limited, a leader in the discovery and optimisation of fully human antibodies, announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes.
-
Inotrem Expands Series B Financing to €58 Million With a Mix of Equity and Debt, Adding New Investors Fountain Healthcare Partners, Kreos and Bpifrance
2/11/2020
New investor Fountain Healthcare Partners provides a further €5 M capital increase adding on the initial €39 M announced last September.
-
Inotrem Secures Strategic Licensing Agreement for a Companion Diagnostics Test in Septic Shock
1/21/2020
Inotrem S.A. announced that it has entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.
-
Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock
11/21/2019
Inotrem S.A. announced it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the treatment of septic shock and has enrolled the first patient in the trial.
-
Inotrem Announces €39 Million Series B Financing to Develop First-In-Class Immunology Therapeutics
9/12/2019
Inotrem S.A. announced a €39 million Series B financing led by Morningside Ventures, joined by Invus with participation from existing investors Andera Partners, Sofinnova Partners and BiomedInvest.
-
Inotrem Announces Fast Track Designation Granted by U.S. FDA to Nangibotide Development Program for the Treatment of Septic Shock
9/3/2019
Inotrem S.A. announced that the U.S. Food and Drug Administration has granted Fast Track designation to nangibotide development program for the treatment of septic shock.